Table 4 Comparison of patient characteristics and outcomes at the 12-month follow-up visit a
| Â | PCT group (n = 85) | Control group (n = 84) | P-value |
|---|---|---|---|
Level of asthma control, n (%) | Â | Â | Â |
Fully controlled | 13 (15.3) | 10 (11.9) | 0.520 |
Controlled | 48 (56.5) | 51 (60.7) | 0.575 |
Partly controlled | 18 (21.2) | 15 (17.8) | 0.586 |
Uncontrolled | 6 (7.1) | 8 (9.5) | 0.561 |
FEV1,% of predicted value | Â | Â | Â |
Prebronchodilator | 76.7 ± 11.8 | 77.9 ± 12.4 | 0.520 |
Postbronchodilator | 83.5 ± 13.4 | 84.7 ± 12.7 | 0.551 |
ACT score, mean (SD) | 21.1 ± 3.3 | 20.6 ± 3.5 | 0.324 |
AQLQ score, mean (SD) | 5.04 ± 1.17 | 5.07 ± 1.21 | 0.788 |
Clinical events during 12-month follow-up period | Â | Â | Â |
Asthma exacerbations, n (%) | 67 (78.8) | 69 (82.1) | 0.586 |
Per patient per year | 1.54 ± 1.17 | 1.52 ± 1.22 | 0.925 |
Emergency room visits, n (%) | 61 (71.8) | 58 (69.0) | 0.698 |
Per patient per year | 1.01 ± 0.81 | 0.96 ± 0.83 | 0.707 |
Hospitalizations, n (%) | 7 (8.2) | 9 (10.7) | 0.582 |
Need for systemic corticosteroids for ≥3 days, n (%) | 43 (50.6) | 46 (54.8) | 0.587 |